PPMD 2020 Virtual Annual Conference has ended
Back To Schedule
Wednesday, July 22 • 7:00pm - 7:50pm
In the Pipeline: Reducing Inflammation

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Inflammation in Duchenne results from a lack of dystrophin and, to date, steroids are the only approved therapy that address this facet of disease. This panel will discuss steroids, potential therapies aimed at reducing inflammation, and potential therapies that may work in combination with steroids.

  • ReveraGen BioPharma (Eric Hoffman, PhD, VP Research)
  • Catabasis Pharmaceuticals (Joanne M Donovan, MD PhD, Chief Medical Officer)
  • PTC Therapeutics (Brian E. Pfister, PhD, MBA, Executive Director, US Medical Head - Neurology)
  • Antisense Therapeutics (Gil Price, MD, Chief Medical Officer)

Followed by Q & A

Visit the On-Demand Library to watch pre-recorded videos relevant to this session before heading into Conference:
Please submit questions ahead of our live panel discussions to comments@parentprojectmd.org.

avatar for Eric Camino, PhD (PPMD)

Eric Camino, PhD (PPMD)

Vice President, Research & Clinical Innovation, Parent Project Muscular Dystrophy

avatar for Joanne M Donovan, MD PhD (Catabasis)

Joanne M Donovan, MD PhD (Catabasis)

Chief Medical Officer, Catabasis

PTC Therapeutics

PTC Therapeutics
avatar for Gil Price, MD (Antisense Therapeutics)

Gil Price, MD (Antisense Therapeutics)

Chief Medical Officer, Antisense Therapeutics

Wednesday July 22, 2020 7:00pm - 7:50pm EDT
Live Stream